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Although there are several reports of kinetic data for HIV 
Abstract A kinetic model is presented for the comparison of protease mutants, no method has been developed to assess in 
potential proteolytic processing activities of wild-type and mutant vivo processing activity and resistant potential for mutant en- 
human immunodeficiency virus proteases in the presence and zymes. 
absence of protease inhibitors. The protease processing of gag 
substrate in the immature virions is assessed by the kinetic para- 
meters, kc,t, K m and Ki. The relationship of the estimated potential 2. A kinetic model for assessing the processing activity of viral 
processing activities to the viability of the HIV mutants and their mutants 
tendencies to resist inhibitors also are discussed. A fully developed 
model has the potential to simulate the results of inhibitor resis- In the presence of inhibitors, the overall processing activity 
tance either in vivo or in cell culture, in a virion is a balance of protease processing efficiency (kcat/ 
Kin) and inhibition efficiency (specified by inhibition constant, 
Key words." HIV protease; Processing activity; Mutation; Drug K~, and inhibitor concentration, [/]). The processing activity, 
resistance aMt, is described by the following equation for a freely diffusible 
system where the effective substrate concentrations are signifi- 
cantly smaller than Kin: 
kcat/ Km 
1. Introduction aMl = cr + [i] (1) 
1 - -  
Ki 
Human immunodeficiency virus contains a protease which where a is determined by initial substrate and protease concen- 
is responsible for the processing of the gag and gag-pol precur- trations. 
sors to yield structural proteins and enzymes of the mature Eqn. 1 can describe the intra-virion processing because the 
virus. The structure of the enzyme [1-3] and its specificity [4] 'effective substrate concentration' inside of the immature viri- 
have been well studied. This enzyme, which is essential for HIV ons is expected to be much lower than the total substrate con- 
maturation and infectivity [5,6], is an important arget for centration. In the immature virions, the p55 gag polyproteins 
AIDS therapy. Many potent HIV protease inhibitors have been form a 'gag shell' with the pl 7 ends anchored in the outer lipid 
tested [7-11]. In vitro, in vivo, and clinical experiments have membrane. The p55 subunits are cylinder shaped and are 
shown that some of these inhibitors have anti-HIV properties densely packed in an icosahedral two-dimensional rray [25]. 
[12-15]. Therapeutic use of an HIV protease inhibitor is ad- The gag portion of the p190 gag-pol precursor co-assembles 
versely impacted by viral drug resistance resulting from muta- with p55 in the 'gag shell' while the pol cylinder (including 
tions of protease gene and selection of resistant strains in the protease) is located in the space inside of the 'gag shell' (Fig. 
presence ofinhibitors [16,17]. Resistance to protease inhibitors 1). To initiate processing, the protease is likely freed by self- 
has also been demonstrated in HIV grown in cultured cells excision from the precursor [26,27] then by protease catalyzed 
[18-24]. The resistance problem needs to be overcome before release. The pores in the 'gag shell' are too small [25] for the 
this line of therapy can be effective, protease to penetrate. Thus, the processing must proceed 
How structural mutation of HIV protease renders it inhibitor through the accessible cleavage sites on the inner surface of the 
resistant is poorly understood. Resistant mutants can appar- 'gag shell'. This near sequential processing mechanism is sup- 
ently retain sufficient enzyme activity but specifically reduce ported by the observation that p39 (p17-p24) is the major 
inhibition sensitivity. Consequently, potential resistant muta- processing intermediate [28,29] and is consistent with the final 
tions can be analyzed by comparing the kinetic parameters for locations of individual gag subunits in the mature virion. The 
activity and inhibition of wild-type and mutant enzymes, total concentration of a single p55 cleavage site inside the im- 
mature virion is estimated to be 5.6 mM [25]. The 'effective 
substrate concentration' is lower since p55 is membrane an- 
chored. (a) The probability of enzyme-substrate collision is 
diminished by more than 50-fold. (b) The abolishment ofgradi- 
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Fig. I. Schematic presentation of the packing relationships of p55 gag and pl90 gag-pol inside of a membrane section of immature HIV virion. 
Immediately inside of the lipid membrane is a layer 'gag shell' which contains tightly packed, cylinder shaped p55 gag precursor units organized in 
icosahedral pattern. Each p55 unit is anchored in the membrane by an N-terminal myristoyl group. The two longer cylinders represent p190 gag-pol 
with the protease dimer located adjacent to the 'gag shell'. The processed protease dimer (dimensions about 39 A. x 53 A) is unable to enter the cavity 
(diameter about 35 A) in the 'gag shell', so the processing of the gag is assumed to be sequential from the p6 to p17 as marked on the p55 cylinder 
in Fig. 1. The packing dimensions of p55 in the 'gag shell' is taken from the work of Nermut et al., [25]. In each immature virion there are about 
1890 molecules of p55 of which 95 are in the p190 form. 
by the conversion of substrate to products. Even without con- the kinetics of the intra-virion processing should be appropri- 
sidering (b), the 'effective substrate concentration' is estimated ately described by kinetics characteristic of [S] << Kin. 
at 80/ IM ~. Since the hydrolysis of bonds in gag polyprotein is Additionally, a teleologic argument supports dilute-substrate 
sequential, the overall processing rate is limited by the slowest kinetics. Several HIV-1 protease mutants are 'Km-mutants' 
step, which is the site between p7 and p6 [30]. The Km for the (such as Val s2 replaced by Glu, Ala, Asp or Gln) in that they 
hydrolysis of this site is 530 ~tM, much higher than the 'effective have relatively unchanged kca, values but large changes of Km 
substrate concentration' when all factors are considered. The compared to the wild-type enzyme [32]. If substrate concentra- 
kinetics for the hydrolysis of membrane-fixed gag should follow tion were high inside the immature virions, processing velocities 
steady-state kinetics. In an analogous case, the hydrolysis of for 'Kin-mutants' would proceed at near Vmax, and these mu- 
membrane-located phosphatidylcholine by phospholipase A 2 tants would have be observed as wild-types. This is not the case 
[31] conforms with Michaelis-Menton kinetics without posses- [33 35]. Taken together, these facts support use of Eqn. 1 to 
sivity by the enzyme toward the substrate surface. Therefore, predict processing activity in the immature virions. 
~Relative contact volumes between enzyme and substrate were used to 3. Potential processing activities of HIV-1 protease mutants and 
estimate the predicted ecrease of effective substrate concentration their relationships to viral viability and resistance to inhibitors 
compared to total substrate concentration. The contact volume for the 
anchored substrate isa spherical shell adjacent to the p55 cylinder ends 
which has thickness equal to the HIV-PR radius. This volume is de- Eqn. 1 can be used to define the resistance potential of differ- 
creased by the fraction of the spherical surface which is filled by p55; ent mutants against an inhibitor or to compare the resistance 
i.e. the area between cylinder ends is omitted from the calculation. The potential of a mutant enzyme against different inhibitors. For 
diffusible substrate contact volume is the volume of a sphere of radius the convenience of comparison, the aM~ values are calculated 
equal to the sum of the p55 and HIV-PR radii multiplied by the number for a constant [/]. Then the potential processing activity can be 
of substrate molecules. For the surface model the volume of the spher- 
ical shell is 4.2 x 107 A. 3 and the fraction of the surface occupied by experimentally defined with kinetic parameters, kcat, Kin, and K~. 
cylinder ends is 0.64. For the diffusible model, the contact volume is MMA,  mutation modulated activity, is the ratio of aMl for a 
1.9 x 109/k 3. The effective substrate concentration is then: particular mutant to the processing activity for uninhibited 
4.2 x 107 0 - wild-type HIV protease xpressed as a percentage. 
5.6 mM (~) ( .64)  - 0.08 mM. We have calculated the potential processing activities of wild- 
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Keys: ~ No Inhibitor ~ U93965 - - -  U88566 
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Fig. 2. 'Mutation modulated activity' (MMA) of HIV-1 protease and 12 mutants in presence and absence of inhibitors. The MMA value of the 
wild-type HIV-1 protease is taken as 100% (see footnote of Table 1). The MMA value of V82A in the absence of inhibitor (horizontal line at 26%) 
is taken as the minimal threshold that can support he HIV life cycle. For each enzyme, the first bar on the left is without inhibitor then the order 
of the inhibitors, from left to right, is U71038, U93840, U93965, U89360, U85548, U88566 and U76088. 
type HIV-1 protease and 27 mutants against individual inhib- example of an in vitro model is the use of the MMA value of 
itors based on reported kinetic data [32,36,37]. An inhibitor mutant V82A, 26%, as a threshold. Mutant V82A has been 
concentration of 10 -7 M is used. Since the Kj of inhibitors of selected in cell culture in the presence of different inhibitors 
interest are in the low nmole range, the use of [/] 10-100-fold [21,39] so the activity of V82A must be able to support the 
greater than Ki is required to achieve significant inhibition. In proliferation of the virus in tissue culture in the absence of any 
Fig. 2, all MMA values calculated from the work of [32] are inhibitor. The V82A threshold line in Fig. 2 serves to illustrate 
plotted together. As can be seen, these values range from insig- the importance of a threshold line to identify mutants which are 
nificant to over 170%. viable in the absence of inhibitor and whether a mutant is 
It is useful to know the threshold MMA value of a viable resistant in the presence ofinhibitors. For all 7 inhibitors at 10 -7 
mutant. We assume that the viral processing activity in patients M, the wild-type enzyme has MMA values below the V82A 
is directly linked to viral maturation and infection of the new threshold. Several mutant enzymes, V82N, V82S, D30F, and 
cells. Thus, a MMA value above the threshold level is required D30W, have MMA values below the V82A threshold in the 
to attain a sufficient rate of new cell infection to counter the absence of inhibitor and are probably not viable mutations for 
elimination of the infected cells by the immune system so that HIV grown in tissue culture. Mutants V82D, V82A, V82D, 
an in vivo steady state is attained [38]. When the in vivo thresh- G48H, G48D, G48Y, K45E and possibly V82Q are likely viable 
old is adequately defined, the present model is a potentially mutants. Resistance against some of the 7 inhibitors are seen 
useful tool for predicting viral viability and inhibitor resistance, for V82E, V82D, K45E and 3 G48 mutants. Interestingly, resis- 
Many laboratories have used in vitro selection of resistant tance in the case of V82E and V82D are achieved by loss of 
strains of HIV in the presence of inhibitors. Unlike the in vivo sensitivity to inhibitors compared to the wildtype enzyme. The 
selections where the mutant proteases must keep pace with cell resistance in G48H and G48Y mutants was achieved by the 
destruction, the in vitro selections need only maintain the viral increase of uninhibited MMA value over the wild-type pro- 
proliferation. So a protease mutant with a MMA value below tease. Similar analysis can be made for kinetic data of other 
the in vivo threshold may still be a successful resistant strain HIV mutants [36,37] to simulate in vitro resistance. 
in vitro. However, the current model can be correlated to both In vitro selection of HIV protease mutants in tissue culture 
in vivo and in vitro HIV viability and resistance because the in the presence of an inhibitor A-77003 with K~ values have been 
difference is only the respective thresholds. There is not suffi- reported [21,22]. The relative kcat/K m values are available only 
cient information to establish an in vivo threshold presently. An for mutant enzymes V32I and V82I [36,37]. We have calculated 
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Table 1 for predicting proliferation of HIV with mutant enzymes and 
Estimated ~ processing activity of resistant HIV-1 protease mutants the potential of the mutant enzymes to resist inhibitors in both 
identified from cell culture xperiments b in vivo and in vitro systems. There are a number of uncertain- 
Inhibitor concentration ties in this model which need substantiation a d improvement. 
Mutants K~ (nM) 10 -6 M 10 -7 M 10 8 M First, the assumption that the effective concentration of the 
substrate is significantly smaller than Km requires experimental Estimated MMA values 
verification. Second, the MMA values for inhibitor esistant 
From Kaplan et al. [22] mutants elected in vivo and in vitro need to be determined in
Wild-type 0.5 0.05 0.50 4.8 
R8Q 31 3.0 24 76 order to establish better threshold values. This requires that 
V32I 3.8 0.02 0.23 1.8 kinetic parameters be collected for the wild-type and mutant 
V321/V82I 11 1.1 9.9 52 HIV proteases using the same substrate, which is not widely 
M46F 2.0 0.20 2.0 17 available in the literature. Also, it is preferable to use substrates 
M46L 1.3 0.13 1.3 12 
V82I 0.5 0.10 1.0 10 taken from the original processing sites. Third, resistance and 
the lack of it predicted by this kinetic model can be further 
From Ho et al. [21] tested in in vivo and in vitro experiments. These new experi- 
Wild-type 0.084 0.01 0.08 0.83 ments would help to further develop this model which may 
R8Q 2.7 0.27 2.6 21 useful in quantitating and predicting the viability and the inhib- 
M46I 0.12 0.01 0.12 1.2 
itor resistance potentials of HIV protease mutants. This model 
aFor mutants R8Q, V32I/V82I, M46F, M46L and M46I, the estimated may also aid the studies on structural changes in HIV protease 
MMA values were calculated assuming kca t ]g  m values for each mutant 
were the same as for the wild-type nzyme. For mutants V32I and V82I,  mutations responsible for inhibitor esistance. 
the mutant to wild type ratio ofkcat/K m was taken from the results of 
Sardana et al. [36]. Acknowledgements. This work is supported in part by NIH Grant 
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